White spot syndrome virus cDNA and Antigen

White spot syndrome virus (WSSV) is a virus that infects a wide variety of crustaceans, including shrimp and crabs. It is the most devastating shrimp pathogen in aquaculture, causing high mortality and significant economic losses in shrimp farming. Symptoms of WSSV include white spots on the body, decreased feeding, lethargy, and death. Treatment for WSSV is limited, but strategies such as improved biosecurity and selective breeding of resistant stocks are being explored.

White spot syndrome virus (WSSV) is a virus that infects crustaceans, such as shrimp and crab. The virus is characterized by the presence of white spots on the exoskeleton of infected animals. WSSV antigen is a protein that is present in the virus and is used to detect and diagnose WSSV infections. WSSV antigen can be detected in a variety of ways, including enzyme-linked immunosorbent assays (ELISAs) and polymerase chain reaction (PCR).

The white spot syndrome virus (WSSV) genome is a large, double-stranded DNA virus that infects a variety of crustacean species including prawns, shrimp, and crabs. It is the most widely distributed virus among crustaceans and has been found in all major shrimp-producing areas of the world. The WSSV genome contains a total of 189,919 base pairs and encodes 186 proteins. These proteins are primarily involved in viral replication, transcription, and translation, and include a variety of structural, regulatory, and accessory proteins. It also contains a large number of non-coding regulatory sequences, including promoters, enhancers, and microRNA elements.

Some of the key proteins of WSSV include the envelope protein, VP26 nucleocapsid protein, VP19 envelope protein, outer membrane protein, VP28, nucleocapsid protein VP35, envelope protein VP466, and the major structural proteins VP24 and VP25. These proteins play crucial roles in the assembly and replication of the virus, as well as its ability to infect and cause disease in crustaceans.

Research into WSSV and its proteins is ongoing, with a focus on understanding the mechanisms of viral replication and host-pathogen interactions. This information may be useful in developing strategies for controlling the spread of the virus and protecting crustacean populations from its devastating effects.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.